Division of Clinical Pharmacy, University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California, USA.
Nephron. 2023;147(1):44-47. doi: 10.1159/000526267. Epub 2022 Sep 9.
Acute kidney injury (AKI) risk prediction models can predict AKI with short lead times and excellent model performance. However, these prediction models have not ascertained the etiology of the AKI. Drugs are an important contributor to AKI, and it is difficult to distinguish drug causes from other etiologies.
Clinical adjudication of AKI etiology can reduce misclassification associated with temporal relationships, since expert adjudicators are trained to assess an outcome in a consistent manner using standardized definitions. Drug-induced acute kidney injury (DI-AKI) varies by drug and is heterogeneous in onset and mechanisms, limiting a universal approach to risk prediction and necessitating expert review. DI-AKI models should be constructed using a high-quality prospective dataset to maximize model performance, internal and external validity. Predictor selection and engineering requires careful attention to unique issues arising from interactions such as drug dose and concentrations. Various statistical methods, such as least absolute shrinkage and selection operator regression or advanced machine learning techniques, may be applied to perform feature selection and capture trends and interactions between predictors. Finally, the model should be carefully evaluated by internal and external validation.
The development of DI-AKI risk prediction models is needed to identify high-risk patients, identify new risk factors, formulate, and apply preventative strategies. DI-AKI risk prediction models require a well-defined dataset of clinically adjudicated cases to improve model performance, validity, and reduce the risk of misclassification.
急性肾损伤 (AKI) 风险预测模型可以在短时间内预测 AKI,并且具有出色的模型性能。然而,这些预测模型并未确定 AKI 的病因。药物是 AKI 的一个重要致病因素,且很难将药物原因与其他病因区分开来。
AKI 病因的临床判断可以减少与时间关系相关的分类错误,因为专家判断人员经过培训,可以使用标准化定义以一致的方式评估结果。药物引起的急性肾损伤 (DI-AKI) 因药物而异,其发病机制和发病机制具有异质性,这限制了风险预测的通用方法,需要进行专家审查。应使用高质量的前瞻性数据集构建 DI-AKI 模型,以最大限度地提高模型性能、内部和外部有效性。预测因子的选择和工程需要仔细注意由于药物剂量和浓度等相互作用引起的独特问题。各种统计方法,如最小绝对收缩和选择算子回归或先进的机器学习技术,可用于进行特征选择并捕获预测因子之间的趋势和相互作用。最后,应通过内部和外部验证仔细评估模型。
需要开发 DI-AKI 风险预测模型,以识别高风险患者,确定新的风险因素,并制定和应用预防策略。DI-AKI 风险预测模型需要具有明确界定的经过临床判断的病例数据集,以提高模型性能、有效性并降低分类错误的风险。